公开(公告)号：US20240361328A1

公开(公告)日：2024-10-31

申请号：US18646665

申请日：2024-04-25

申请人： JUN HUANG

发明人： JUN HUANG ,  YIFEI HU

IPC分类号： G01N33/58 ,  C07K1/13 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C12N5/0783 ,  G01N33/569

CPC分类号： G01N33/58 ,  C07K1/13 ,  C07K16/2803 ,  C07K16/30 ,  C07K16/32 ,  C12N5/0636 ,  G01N33/56972 ,  G01N33/582 ,  C07K2317/92 ,  C07K2319/22 ,  C07K2319/33 ,  C07K2319/60

摘要： The present invention discloses a versatile application of a multimer technology for detecting, manufacturing, and profiling chimeric antigen receptor (CAR)-expressing cells. These antigen-multimers exhibit remarkable specificity, sensitivity, and precision in identifying CAR cells. Moreover, they facilitate over 100-fold magnetic enrichment of rare CAR-T cells, enhancing their detectability. Beyond CAR detection, the multimer technology selectively stimulates CAR-expressing cells, both in soluble and surface-bound formats, during CAR-T cell manufacturing. Unlike existing technologies (such as anti-CD28/CD3 magnetic beads) that non-specifically stimulate and expand all T cells, the multimer approach ensures that only CAR-expressing cells are targeted. Consequently, this yields a CAR-T cell product with significantly higher purity, enhancing treatment efficacy. Furthermore, the multimer technology offers flexibility in CAR detection through nucleotide labeling. This enables high-dimensional CAR-T cell profiling via single-cell multi-omics analyses. Antigen multimers can be seamlessly adapted to other CAR systems by switching the antigen ligand.

公开(公告)号：US20240360191A1

公开(公告)日：2024-10-31

申请号：US18769216

申请日：2024-07-10

申请人： NantBio, Inc.

发明人： Kayvan Niazi ,  Clifford Anders Olson ,  Shiho Tanaka ,  Heather McFarlane

IPC分类号： C07K14/54 ,  A61K35/17 ,  C12N5/0783

CPC分类号： C07K14/5434 ,  A61K35/17 ,  C12N5/0646 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2319/01 ,  C07K2319/33

摘要： Compositions and methods for NK cell based treatments, and particularly NK cells that express and intracellularly retain IL-2, are presented in which the NK cells are stimulated with a chimeric protein that has a cancer cell targeting portion and an IL-12 portion. Beneficially, such chimeric protein has substantially reduced systemic toxicity and induces IFN-γ secretion in a targeted manner. Moreover, chimeric proteins contemplated herein also significantly enhanced IFN-γ secretion in NK cells that express and intracellularly retain IL-2 as compared to native NK cells. Preferred chimeric proteins comprise SEQ ID NO:1 or SEQ ID NO:2, and SEQ ID NO:3.

公开(公告)号：US20240358756A1

公开(公告)日：2024-10-31

申请号：US18599924

申请日：2024-03-08

申请人： Immatics Biotechnologies GmbH

发明人： Ricarda HANNEN ,  Jens HUKELMANN ,  Florian KOEHLER ,  Daniel Johannes KOWALEWSKI ,  Heiko SCHUSTER ,  Oliver SCHOOR ,  Michael ROEMER ,  Chih-Chiang TSOU ,  Jens FRITSCHE

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/47 ,  C12N5/0783

CPC分类号： A61K35/17 ,  A61K39/0011 ,  A61P35/00 ,  C07K14/4748 ,  C12N5/0636

摘要： The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US12129486B2

公开(公告)日：2024-10-29

申请号：US17063204

申请日：2020-10-05

申请人： FUJIFILM Cellular Dynamics, Inc.

发明人： Maksym A. Vodyanyk ,  Xin Zhang ,  Andrew J. Brandl ,  Deepika Rajesh ,  Bradley Swanson ,  Christie Munn ,  Sarah A. Burton ,  Wen Bo Wang

IPC分类号： C12N5/0783 ,  C12N5/0781 ,  C12N5/0784 ,  C12N5/0789 ,  C12N15/85 ,  C12N15/86

CPC分类号： C12N5/0636 ,  C12N5/0635 ,  C12N5/0637 ,  C12N5/0638 ,  C12N5/0639 ,  C12N5/0646 ,  C12N5/0647 ,  C12N15/85 ,  C12N15/86 ,  C12N2500/38 ,  C12N2500/90 ,  C12N2501/115 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/155 ,  C12N2501/165 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/2307 ,  C12N2501/25 ,  C12N2501/26 ,  C12N2501/60 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/605 ,  C12N2501/606 ,  C12N2501/608 ,  C12N2501/727 ,  C12N2501/998 ,  C12N2501/999 ,  C12N2506/025 ,  C12N2506/03 ,  C12N2506/09 ,  C12N2506/11 ,  C12N2506/45 ,  C12N2510/00 ,  C12N2533/50 ,  C12N2840/20

摘要： Provided herein are methods for the efficient in vitro differentiation of somatic cell-derived pluripotent stem cells to hematopoietic precursor cells, and the further differentiation of the hematopoietic precursor cells into immune cells of various myeloid or lymphoid lineages, particularly T cells, NK cells, and dendritic cells. The pluripotent cells may be maintained and differentiated under defined conditions; thus, the use of mouse feeder cells or serum is not required in certain embodiments for the differentiation of the hematopoietic precursor cells.

公开(公告)号：US12129291B2

公开(公告)日：2024-10-29

申请号：US18335477

申请日：2023-06-15

申请人： Yamaguchi University ,  National Cancer Center ,  Noile-Immune Biotech, Inc.

发明人： Koji Tamada ,  Yukimi Sakoda ,  Tetsuya Nakatsura ,  Keigo Saito

IPC分类号： C07K16/18 ,  C07K14/54 ,  C07K14/725 ,  C07K16/30 ,  C12N5/078 ,  C12N5/0783 ,  G01N33/68

CPC分类号： C07K16/18 ,  C07K14/5418 ,  C07K14/7051 ,  C07K16/303 ,  C12N5/0634 ,  C12N5/0636 ,  G01N33/68 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03

摘要： An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.

公开(公告)号：US20240352129A1

公开(公告)日：2024-10-24

申请号：US18628258

申请日：2024-04-05

申请人： The Brigham and Women's Hospital, Inc.

发明人： Jamil Azzi ,  Nour Younis ,  Omar Abudayyeh

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61P37/06 ,  C12N5/0783 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90

CPC分类号： C07K16/2833 ,  A61K39/4611 ,  A61P37/06 ,  C12N5/0636 ,  C12N9/22 ,  C12N15/11 ,  C12N15/907 ,  C07K2317/24 ,  C12N2310/20 ,  C12N2510/00

摘要： Disclosed are compositions and methods of promoting transplantation tolerance, treating an immune disorder associated with graft transplantation, and promoting organ survival in an organ transplanted into a subject. The methods include administering anti-CD74 antibodies or CD74-deficient Treg cells.

公开(公告)号：US20240350546A1

公开(公告)日：2024-10-24

申请号：US18686868

申请日：2022-08-31

申请人： The Texas A&M University System ,  The Research Institute at Nationwide Children's Hospital

发明人： Xiaotong Song ,  Ruoning Wang ,  Abhijit Sarkar ,  Yue Hu

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/55 ,  C07K14/705 ,  C12N5/0783 ,  C12N9/78

CPC分类号： A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/4644 ,  A61P35/00 ,  C07K14/55 ,  C07K14/70596 ,  C12N5/0636 ,  C12N9/78 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/30 ,  C12Y305/04004

摘要： The present application provides methods and compositions for treating cancers using a CAR T cell therapy platform. Also provided are methods and use of the CAR T cells for treating diseases and conditions, such as cancer, and in particular any disease or condition associated with elevated adenosine or other associate marker.

公开(公告)号：US20240350545A1

公开(公告)日：2024-10-24

申请号：US18683208

申请日：2022-08-18

申请人： LEGEND BIOTECH IRELAND LIMITED

发明人： Yanliang ZHU ,  Qingling JIANG ,  Zhongyuan TU ,  Yafeng ZHANG ,  Shu WU ,  Xiaohu FAN

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/86

CPC分类号： A61K35/17 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/4631 ,  A61K39/4632 ,  A61K39/464412 ,  A61K39/464417 ,  A61K39/464424 ,  A61K39/464429 ,  A61K39/464474 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70596 ,  C07K16/2803 ,  C07K16/2851 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/303 ,  C12N5/0638 ,  C12N5/0646 ,  C12N15/86 ,  A61K2239/13 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2510/00 ,  C12N2740/15043

摘要： The present application provides modified immune cells that express TLR receptors. In some embodiments, the modified immune cell further comprises an engineered receptor such as a chimeric antigen receptor (CAR). The present application also provides methods and pharmaceutical compositions for cancer treatment using the modified immune cells described herein.

公开(公告)号：US12121541B2

公开(公告)日：2024-10-22

申请号：US17041305

申请日：2018-06-29

申请人： Iovance Biotherapeutics, Inc.

发明人： Seth Wardell ,  James Bender

IPC分类号： A61K35/17 ,  A01N1/02 ,  A61K9/00 ,  A61K31/675 ,  A61K31/7076 ,  A61K38/20 ,  A61P35/00 ,  C12N5/078 ,  C12N5/0783 ,  A61K38/21 ,  A61K39/00

CPC分类号： A61K35/17 ,  A01N1/0284 ,  A61K9/0019 ,  A61K31/675 ,  A61K31/7076 ,  A61K38/2013 ,  A61P35/00 ,  C12N5/0634 ,  C12N5/0636 ,  C12N5/0638 ,  A61K38/217 ,  A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/55533 ,  C12N2501/04 ,  C12N2501/2302 ,  C12N2501/2315 ,  C12N2501/2321 ,  C12N2501/24 ,  C12N2501/603 ,  C12N2502/11 ,  C12N2506/30

摘要： The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

公开(公告)号：US12121540B2

公开(公告)日：2024-10-22

申请号：US17030335

申请日：2020-09-23

申请人： Nurix Therapeutics, Inc.

发明人： Jennifa Gosling ,  Arthur Sands ,  Sarah Anne Whelan ,  Cristiana Guiducci

IPC分类号： A61K35/17 ,  A61K31/4196 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61P35/00 ,  A61P37/04 ,  C12N5/0783

CPC分类号： A61K35/17 ,  A61K31/4196 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61P35/00 ,  A61P37/04 ,  C12N5/0636 ,  C12N2501/2302 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/2321 ,  C12N2501/72 ,  C12N2506/11

摘要： Methods and compositions using novel Cbl inhibitors for supporting engraftment of immune cells to increase the efficacy of cell-based immunotherapeutics are disclosed. Also provided are cell-based immunotherapy methods and compositions using novel Cbl inhibitors for the propagation of cells desirable for use in cell-based immunotherapies.